Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
1949
5.7K+
LTM Revenue $3.1B
LTM EBITDA $696M
$7.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of October 2025, Kyowa Kirin Co reported last 12-month revenue of $3.1B and EBITDA of $696M.
In the same period, Kyowa Kirin Co generated $2.3B in LTM gross profit and $360M in net income.
See Kyowa Kirin Co valuation multiples based on analyst estimatesIn the most recent fiscal year, Kyowa Kirin Co reported revenue of $3.2B and EBITDA of $739M.
Kyowa Kirin Co expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Kyowa Kirin Co valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.1B | XXX | $3.2B | XXX | XXX | XXX |
| Gross Profit | $2.3B | XXX | $2.3B | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | $696M | XXX | $739M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $529M | XXX | $586M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $360M | XXX | $382M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Kyowa Kirin Co has current market cap of JPY 1.34T (or $8.6B), and EV of JPY 1.11T (or $7.1B).
As of November 25, 2025, Kyowa Kirin Co's stock price is JPY 2567 (or $16).
See Kyowa Kirin Co trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.1B | $8.6B | XXX | XXX | XXX | XXX | $0.68 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialKyowa Kirin Co's trades at 2.2x EV/Revenue multiple, and 9.6x EV/EBITDA.
See valuation multiples for Kyowa Kirin Co and 15K+ public compsAs of November 25, 2025, Kyowa Kirin Co has market cap of $8.6B and EV of $7.1B.
Equity research analysts estimate Kyowa Kirin Co's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kyowa Kirin Co has a P/E ratio of 23.8x.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.6B | XXX | $8.6B | XXX | XXX | XXX |
| EV (current) | $7.1B | XXX | $7.1B | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 10.2x | XXX | 9.6x | XXX | XXX | XXX |
| EV/EBIT | 13.4x | XXX | 12.1x | XXX | XXX | XXX |
| EV/Gross Profit | 3.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 23.8x | XXX | 22.4x | XXX | XXX | XXX |
| EV/FCF | -71.8x | XXX | -29.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKyowa Kirin Co's last 12 month revenue growth is 4%
Kyowa Kirin Co's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.3M for the same period.
Kyowa Kirin Co's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kyowa Kirin Co's rule of X is 33% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kyowa Kirin Co and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | -5% | XXX | XXX | XXX |
| Rule of 40 | 31% | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 33% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kyowa Kirin Co acquired XXX companies to date.
Last acquisition by Kyowa Kirin Co was XXXXXXXX, XXXXX XXXXX XXXXXX . Kyowa Kirin Co acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Kyowa Kirin Co founded? | Kyowa Kirin Co was founded in 1949. |
| Where is Kyowa Kirin Co headquartered? | Kyowa Kirin Co is headquartered in Japan. |
| How many employees does Kyowa Kirin Co have? | As of today, Kyowa Kirin Co has 5.7K+ employees. |
| Who is the CEO of Kyowa Kirin Co? | Kyowa Kirin Co's CEO is Mr. Masashi Miyamoto. |
| Is Kyowa Kirin Co publicy listed? | Yes, Kyowa Kirin Co is a public company listed on TKS. |
| What is the stock symbol of Kyowa Kirin Co? | Kyowa Kirin Co trades under 4151 ticker. |
| When did Kyowa Kirin Co go public? | Kyowa Kirin Co went public in 1949. |
| Who are competitors of Kyowa Kirin Co? | Similar companies to Kyowa Kirin Co include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Kyowa Kirin Co? | Kyowa Kirin Co's current market cap is $8.6B |
| What is the current revenue of Kyowa Kirin Co? | Kyowa Kirin Co's last 12 months revenue is $3.1B. |
| What is the current revenue growth of Kyowa Kirin Co? | Kyowa Kirin Co revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Kyowa Kirin Co? | Current revenue multiple of Kyowa Kirin Co is 2.3x. |
| Is Kyowa Kirin Co profitable? | Yes, Kyowa Kirin Co is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kyowa Kirin Co? | Kyowa Kirin Co's last 12 months EBITDA is $696M. |
| What is Kyowa Kirin Co's EBITDA margin? | Kyowa Kirin Co's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Kyowa Kirin Co? | Current EBITDA multiple of Kyowa Kirin Co is 10.2x. |
| What is the current FCF of Kyowa Kirin Co? | Kyowa Kirin Co's last 12 months FCF is -$98.5M. |
| What is Kyowa Kirin Co's FCF margin? | Kyowa Kirin Co's last 12 months FCF margin is -3%. |
| What is the current EV/FCF multiple of Kyowa Kirin Co? | Current FCF multiple of Kyowa Kirin Co is -71.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.